Portal de Periódicos da CAPES

Alarmins in autoimmune diseases

2022; Elsevier BV; Volume: 21; Issue: 9 Linguagem: Inglês

10.1016/j.autrev.2022.103142

1873-0183

Maria Giovanna Danieli, Eleonora Antonelli, Mario Andrea Piga, Ilaria Claudi, Davide Palmeri, Alessandro Tonacci, Alessandro Allegra, Sebastiano Gangemi,

Cytokine Signaling Pathways and Interactions

Alarmins are endogenous, constitutively expressed, chemotacting and immune activating proteins or peptides released because of non-programmed cell death (i.e. infections, trauma, etc). They are considered endogenous damage-associated molecular patterns (DAMPs), able to induce a sterile inflammation. In the last years, several studies highlighted a possible role of different alarmins in the pathogenesis of various autoimmune and immune-mediated diseases. We reviewed the relevant literature about this topic, for about 160 articles. Particularly, we focused on systemic autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myopathies, ANCA-associated vasculitides, Behçet's disease) and cutaneous organ-specific autoimmune diseases (vitiligo, psoriasis, alopecia, pemphigo). Finally, we discussed about future perspectives and potential therapeutic implications of alarmins in autoimmune diseases. In fact, identification of receptors and downstream signal transducers of alarmins may lead to the identification of antagonistic inhibitors and agonists, with the capacity to modulate alarmins-related pathways and potential therapeutic applicability.